Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that CD20 + status confers therapeutic sensitivity to Carboplatin, Etoposide, Ifosfamide, Rituximab in patients with Non-Hodgkin Lymphoma.
The Republic of Ireland's Health Service Executive (HSE) has approved carboplatin in combination with ifosfamide and etoposide (ICE) for reimbursement as a treatment option for the treatment of relapsed/refractory Non Hodgkin's Lymphoma. The therapy regimen further states that rituximab is to be included for the treatment of CD20 positive patients.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of relapsed / refractory Non Hodgkin's Lymphoma. Rituximab to be included in CD20 positive patients.